Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Income from Continuing Operations data on file, last reported at 150049000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 27.06% year-over-year to 150049000.0 in Q1 2026; TTM through Mar 2026 was 348876000.0, a 28.12% decrease from a year earlier, with the FY2025 full-year figure at 316889000.0, down 28.64% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 150049000.0, up from 141591000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for HALO reached as high as 175258000.0 in Q3 2025 and fell as low as 141591000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 82046176.47 across 5 years, with a median of 81837000.0 in 2023.
• Across the five-year window, Income from Continuing Operations soared 229.53% in 2023 and slumped 203.34% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 57702000.0 in 2022, then surged by 47.98% to 85388000.0 in 2023, then surged by 60.46% to 137012000.0 in 2024, then slumped by 203.34% to 141591000.0 in 2025, then jumped by 205.97% to 150049000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 150049000.0 in Q1 2026, 141591000.0 in Q4 2025, and 175258000.0 in Q3 2025.